We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis.
- Authors
Lopes, L C; Spencer, F A; Neumann, I; Ventresca, M; Ebrahim, S; Zhou, Q; Bhatnaga, N; Schulman, S; Eikelboom, J; Guyatt, G
- Abstract
Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03-3.11) bleeds per 100 patient-years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect.
- Subjects
HEMORRHAGE risk factors; ATRIAL fibrillation; VITAMIN K; CHEMICAL inhibitors; META-analysis; SYSTEMATIC reviews; PATIENTS
- Publication
Clinical Pharmacology & Therapeutics, 2013, Vol 94, Issue 3, p367
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2013.99